3- year efficacy and safety for liraglitude 3.0mg in adults with obesity/overweight, prediabetes and baseline BMI <35 vs >/=35kg/m2 in the SCALE obesity and and pore diabetes, double-blind, placebo-controlled trial
dc.contributor.author | Fasanmade, O | |
dc.contributor.author | Greenway, F | |
dc.contributor.author | Le Roux, C.W | |
dc.contributor.author | McGowan, B | |
dc.contributor.author | Pi-Sunyer, X | |
dc.contributor.author | Cancino, A.P | |
dc.date.accessioned | 2020-07-16T16:21:38Z | |
dc.date.available | 2020-07-16T16:21:38Z | |
dc.date.issued | 2007-09 | |
dc.identifier.citation | Fasanmade O, Greenway F, Le Roux CW, McGowan B, Pi-Sunyer X, Cancino AP, Van Gaal L. 3- year efficacy and safety for liraglitude 3.0mg in adults with obesity/overweight, prediabetes and baseline BMI <35 vs >/=35kg/m2 in the SCALE obesity and and pore diabetes, double-blind, placebo-controlled trial. 2017 book of abstracts Endocrinology and Metabolism Society of Nigeria. | en_US |
dc.identifier.uri | https://ir.unilag.edu.ng/handle/123456789/8632 | |
dc.language.iso | en_US | en_US |
dc.publisher | Endocrine and Metabolism Society of Nigeria | en_US |
dc.subject | Liraglutide, obesity, efficacy | en_US |
dc.title | 3- year efficacy and safety for liraglitude 3.0mg in adults with obesity/overweight, prediabetes and baseline BMI <35 vs >/=35kg/m2 in the SCALE obesity and and pore diabetes, double-blind, placebo-controlled trial | en_US |
dc.type | Presentation | en_US |
Files
Original bundle
1 - 1 of 1
Loading...
- Name:
- 3-year efficacy and safety for liraglutide 3.0mg in adults.pdf
- Size:
- 415.36 KB
- Format:
- Adobe Portable Document Format
- Description:
- Abstract
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 1.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: